Mark Smith, MD
Urology · Sheffield, ALNPI 1396715843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 332 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 332 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$736
- Endo Pharmaceuticals Inc.$690
- Teleflex LLC$462
- Boston Scientific$384
- plus $4K from 28 others
What the payments were for
- Travel & lodging$150%
- Food & beverage$7,87396%
- Education$3314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 34 | $1,331 |
| Astellas Pharma US Inc | 52 | $1,035 |
| Sumitomo Pharma America, Inc. | 37 | $736 |
| Endo Pharmaceuticals Inc. | 38 | $690 |
| Teleflex LLC | 7 | $462 |
| Boston Scientific | 15 | $384 |
| Urovant Sciences Inc | 19 | $380 |
| Axonics, Inc. | 11 | $310 |
| Medtronic | 9 | $281 |
| Pfizer | 14 | $262 |
| Bayer | 9 | $192 |
| Dendreon Pharmaceuticals LLC | 8 | $188 |
| Ferring Pharmaceuticals Inc. | 8 | $178 |
| Myriad Genetic Laboratories, Inc. | 4 | $172 |
| Endo USA, Inc. | 7 | $148 |
| Calyxo, Inc. | 1 | $138 |
| Bluewind Medical | 3 | $136 |
| Antares Pharma, Inc. | 7 | $134 |
| Procept Biorobotics Corporation | 5 | $121 |
| AbbVie(2 entities) | 7 | $121 |
| KARL Storz Lithotripsy-america | 1 | $115 |
| Tolmar, Inc. | 5 | $110 |
| Johnson & Johnson | 7 | $110 |
| Olympus America Inc. | 4 | $85 |
| Dornier Medtech America, Inc | 1 | $76 |
| Myovant Sciences Inc. | 4 | $63 |
| Progenics Pharmaceuticals, Inc. | 3 | $57 |
| Urogen Pharma, Inc. | 3 | $56 |
| Rochester Medical Corporation | 3 | $44 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Halozyme Inc | 1 | $23 |
| CSL Behring | 1 | $20 |
| Conmed Corporation | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$758
- Axonics$146
- PENILE & TESTICULAR RECONSTRUCTN$141
- CVAC Aspiration System$138
- UroLift System$138
- UroLift$118
- BRAC CDx$102
How this compares
$8,218 in reported general payments places this provider in the 80th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $189,260 |
| GemtesaVibegron | 88 | $57,505 |
| MyrbetriqMirabegron | 56 | $44,584 |
| Tolterodine Tartrate ErTolterodine Tartrate | 194 | $16,922 |
| Tamsulosin Hcl | 951 | $14,592 |
| Lidocaine Hcl | 343 | $5,239 |
| Oxybutynin Chloride ErOxybutynin Chloride | 209 | $4,741 |
| Testosterone | 20 | $3,949 |
| Finasteride | 184 | $2,861 |
| Potassium Citrate ErPotassium Citrate | 12 | $2,796 |
| Testosterone Cypionate | 75 | $2,293 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 102 | $2,117 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $2,077 |
| Cefdinir | 155 | $1,921 |
| Desmopressin Acetate | 13 | $1,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,035 | $233,84470 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $736 | $57,50588 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 179 urology providers in Alabama.
Other urology in Sheffield
- Kevin WallsSheffield$5K
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Adam BaumgartenBirmingham$271K
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
- Kyle WoodBirmingham$91K
- Christopher KeelFairhope$68K
- Rachel EngelbergHomewood$61K
- Jeffrey NixBirmingham$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.